Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies
Microorganisms · 09.05.2026 · 14 (5) · 1071
DOI: 10.3390/microorganisms14051071 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 09.05.2026. Verfasst von Claudio Tana und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Unit, Eastern Hospital, ASL Taranto, 74024 Manduria, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Perugia.
Abstract (Originalsprache)
Gram-positive infections are associated with significant morbidity and healthcare burden, often requiring prolonged intravenous therapy. Dalbavancin, a long-acting lipoglycopeptide, has emerged as a promising option beyond its approved indication for acute bacterial skin and skin structure infections (ABSSSI). A systematic review was conducted according to the PRISMA guidelines (PROSPERO: CRD420261296328). MEDLINE, Embase, CENTRAL, and Web of Science were searched from inception. Randomized controlled trials (RCTs) and observational studies evaluating dalbavancin in adult patients with Gram-positive infections were included. Outcomes of interest were clinical effectiveness, safety, and healthcare resource utilization. Risk of Bias was assessed using RoB 2 and the Newcastle–Ottawa Scale. Twenty-one studies were included. Randomized trials confirmed non-inferior efficacy of dalbavancin compared with standard therapy in ABSSSI. Observational studies demonstrated high clinical success rates across a range of infections, including osteo-articular infections, bloodstream infections, and infective endocarditis (IE), particularly in acute settings. Lower effectiveness was observed in biofilm-related infections without adequate source control. Dalbavancin was frequently used as sequential or consolidation therapy in complex patients. Its use was consistently associated with reduced length of hospital stay, facilitation of outpatient management, and potential cost savings. The safety profile was favorable, including in prolonged or multi-dose regimens. In conclusion, dalbavancin represents an effective and well-tolerated option for Gram-positive infections, with expanding evidence supporting its use in complex and off-label settings. Its pharmacokinetic profile enables simplified treatment strategies and improved healthcare resource utilization, although appropriate patient selection and source control remain essential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine Unit, Eastern Hospital, ASL Taranto, 74024 Manduria, Italy.
- Infectious Disease Clinic, G. D'Annunzio University of Chieti and ASL2 Lanciano Vasto Chieti, 66100 Chieti, Italy.
- Internal Medicine Unit, G. D'Annunzio University of Chieti and ASL2 Lanciano Vasto Chieti, 66100 Chieti, Italy.
- Department of Pharmacy, G. D'Annunzio University of Chieti, 66100 Chieti, Italy.
- Infectious Disease Clinic, University of Perugia, 06123 Perugia, Italy.
ORCID-Profile: Claudio Tana, Marco Tana, Claudio Ucciferri
Förderung
- University of Perugia
Zitieren
APA
Tana, C., Moffa, L., Tana, M., Moffa, S., & Ucciferri, C. (2026). Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies. Microorganisms, 14(5), 1071. https://doi.org/10.3390/microorganisms14051071
Vancouver
Tana C, Moffa L, Tana M, Moffa S, Ucciferri C. Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies. Microorganisms. 2026;14(5):1071. doi:10.3390/microorganisms14051071
BibTeX
@article{Tana2026,
author = {Tana, Claudio and Moffa, Livia and Tana, Marco and Moffa, Samanta and Ucciferri, Claudio},
title = {Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies},
journal = {Microorganisms},
year = {2026},
volume = {14},
number = {5},
pages = {1071},
doi = {10.3390/microorganisms14051071}
}
EUVIMED